Formulation & Performance
Mouse and nonhuman-primate evidence for L829, with targeting, efficacy and tolerability kept separate.
The catalog mapping to L829 is retained from the existing approved record. The Science main article does not independently establish the commercial structure or the Compound A-11 alias.
Formulation components and molecular-weight conversion
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| L829 / CICL-1 | DC99010 | 1013.4 | Not assigned | Not calculable from disclosed data |
| Targeting ligand-lipid conjugate | Not uniquely mapped | Not established | Not assigned | Not calculable from disclosed data |
| Other three lipid components | Not uniquely mapped | Not established | Not assigned | Not calculable from disclosed data |
The molecular weight shown for CICL-1 is a catalog value. Complete five-lipid identity, proportions and N/P await Supplementary Table S1; no patent formulation is substituted.
Component mass calculator
Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.
| Component | MW | Molar ratio | Mass (mg) | Mass % |
|---|---|---|---|---|
| L829 / CICL-1 | ||||
| Targeting ligand-lipid conjugate | ||||
| Other three lipid components |
Study identity and formulation boundary
| Item | Evidence |
|---|---|
| Source compound | L829 in Hunter et al., Science (2025). CICL-1 / Compound A-11 is the catalog mapping; those names and a chemical structure are not disclosed in the reviewed main paper. |
| Targeting | Untargeted LNP, CD5-targeted LNP and CD8-targeted LNP are separate systems. Targeting ligand and cargo influence performance. |
| Composition | Five-lipid formulation is referenced to Supplementary Table S1. Exact component identities, molar ratios and N/P remain unverified without that table. |
| Particle properties | Size, PDI, encapsulation and apparent pKa are not assigned from unrelated patents. |
Hunter et al., main article and references to supplementary methods; existing reviewed main-article record retained. New SI retrieval was blocked on 28 October 2026.
Mouse delivery and leukemia experiments
| Experiment | Reported outcome | Context / source |
|---|---|---|
| Untargeted reporter LNP | Less liver and spleen luciferase expression than the ALC-0315 benchmark. | Wild-type C57BL/6 mice; main Fig. 1B. Reporter expression is distinct from particle accumulation. |
| Lipid persistence | L829 cleared more rapidly from mouse liver; ALC-0315 remained elevated for at least 7 days. | Main Fig. 1C; compound clearance endpoint, not RNA expression duration. |
| Humanized leukemia model | Near-complete tumor clearance in 4/5 mice two days after the first dose; 5/5 three days after the second dose. | CD8-targeted anti-CD19 CAR mRNA; PBMC/Nalm6 xenograft, 30 micrograms IV, twice weekly for five doses; Fig. 3G. |
Nonhuman-primate CAR expression and B-cell depletion
| Endpoint | Reported result | Study context |
|---|---|---|
| Peripheral B cells | Decline by 6 hours and near-undetectable levels by 24 hours after the first dose. | CD8-targeted anti-CD20 CAR mRNA; 22 cynomolgus monkeys across three studies, 0.1-2.0 mg/kg, three IV doses 72 hours apart; Fig. 4. |
| CD8 T-cell CAR expression | Up to 85% after the third dose. | Upper observed value, not mean or guarantee; minimal CD4 T-cell CAR expression reported. |
| CD8 NK-cell CAR expression | Up to 95% after the third dose. | Dose-dependent response; Fig. 4C. |
| B-cell recovery | Repopulation started around day 21 and approached baseline by day 35. | 1-1.5 mg/kg follow-up; Fig. 5. Predominantly naive repopulation was interpreted by the authors as suggestive of immune reset. |
Tolerability: retain the adverse result
| Study | Finding | Interpretation |
|---|---|---|
| Rat CD5-targeted L829 | Reported tolerated up to 5 mg/kg without adverse observations. | Main Fig. 1D; does not establish the safety of every cargo/targeting combination. |
| Single-dose cynomolgus study | A 3 mg/kg IV dose was reported as tolerated. | Main Fig. 1E; separate from repeat CAR dosing. |
| Repeat anti-CD20 CAR dosing | One monkey in the 1.5 mg/kg group developed a serious immune-effector-cell-associated event 72 hours after dose 3 and was euthanized. | Main text p. 1316. This event must be considered alongside depletion efficacy; no blanket nontoxic claim. |
Original study figures
Mouse and primate results: Figures 1 and 3-5 — Original source figures.
